Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Olix US Inc. currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are handled by 3 distinct examiners across 3 distinct art units. This distribution between actions, examiners, and units suggests that each matter is being prosecuted in a different technical environment within the USPTO. The involvement of 3 distinct art units indicates that the company's research spans multiple specialized fields within the pharmaceutical sector, which may require a diverse set of legal strategies. Practitioners should note that the workload is shared among several individuals.
MCINTOSH III, TRAVISS C is the busiest examiner for this portfolio, holding 1 busiest examiner pending action. Since there are 3 pending office actions in total, the workload is spread across the individuals involved. Practitioners should note that the distinct art units may have different examination timelines or procedural requirements. The 3 pending office actions in Biotechnology & Pharmaceuticals represent the current active prosecution pipeline for Olix US Inc., with 1 busiest examiner pending action assigned to the lead examiner. This structure allows for a diversified prosecution strategy where the outcome of one matter is less likely to be influenced by the specific biases of a single examiner. Practitioners can leverage the involvement of 3 distinct art units to identify potential trends in how the USPTO is treating the company's specific technical niche.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCINTOSH III, TRAVISS C | 1 | 73.3% | +14.1% |
| BRANDSEN, BENJAMIN MICHAEL | 1 | 60.9% | +21.7% |
| VANHORN, ABIGAIL LOUISE | 1 | 46.8% | +22.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18443778 | LITHIUM REAGENTS AND THEIR USES IN SOLID PHASE SYNTHESIS | MCINTOSH III, TRAVISS C | — |
| 18562731 | FUNCTIONAL MOIETIES AND THEIR USES AND SYNTHETIC PREPARATION | BRANDSEN, BENJAMIN MICHAEL | — |
| 18320753 | LINKERS COUPLING FUNCTIONAL LIGANDS TO MACROMOLECULES | VANHORN, ABIGAIL LOUISE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18443778 | LITHIUM REAGENTS AND THEIR USES IN SOLID PHASE SYNTHESIS | MCINTOSH III, TRAVISS C | — |
| 18562731 | FUNCTIONAL MOIETIES AND THEIR USES AND SYNTHETIC PREPARATION | BRANDSEN, BENJAMIN MICHAEL | — |
| 18320753 | LINKERS COUPLING FUNCTIONAL LIGANDS TO MACROMOLECULES | VANHORN, ABIGAIL LOUISE | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| 1658 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18443778 | LITHIUM REAGENTS AND THEIR USES IN SOLID PHASE SYNTHESIS | MCINTOSH III, TRAVISS C | 1693 | §102§103 | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18562731 | FUNCTIONAL MOIETIES AND THEIR USES AND SYNTHETIC PREPARATION | BRANDSEN, BENJAMIN MICHAEL | 1658 | §101§102§103§112 | Non-Final OA | — | Pending | Nov 20, 2023 |
| 18320753 | LINKERS COUPLING FUNCTIONAL LIGANDS TO MACROMOLECULES | VANHORN, ABIGAIL LOUISE | 1637 | §102§103§112 | Non-Final OA | — | Pending | May 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOlix US Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Traviss C Mcintosh III has the most, with 1 of Olix US Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
